Table 3.
Baseline clinical and haemodynamic characteristics in relation to the Sac/Val dosage
| Maximum dose not reached, n = 59 | Maximum dose reached, n = 36 | P | |
|---|---|---|---|
| Age, years | 69.4 [62.5–74.5] | 59.7 [49.3–66.4] | 0.002 |
| Female, N (%) | 10 (16.9) | 5 (13.9) | 0.69 |
| BMI, kg/m2 | 27.5 [25.1–30.8] | 25.5 [23–28.8] | 0.07 |
| SBP, mmHg | 110 [110–120] | 122.5 [110–133.7] | 0.047 |
| DBP, mmHg | 65 [60–70] | 72.5 [62.5–80] | 0.016 |
| HR, b.p.m. | 70 [61–80] | 66.5 [61.2–75] | 0.89 |
| Hypertension, N (%) | 50 (84.7) | 28 (77.8) | 0.39 |
| Dyslipidaemia, N (%) | 43 (72.9) | 20 (55.6) | 0.08 |
| Diabetes, N (%) | 22 (37.3) | 13 (36.1) | 0.91 |
| Ischaemic aetiology, N (%) | 26 (44.1) | 12 (33.3) | 0.3 |
| Smoking, N (%) | 10 (16.9) | 7 (19.4) | 0.9 |
| ICD, N (%) | 21 (35.6) | 17 (47.2) | 0.75 |
| CRT‐D, N (%) | 13 (22) | 5 (13.9) | |
| CKD, N (%) | 28 (47.5) | 14 (38.9) | 0.41 |
| Atrial fibrillation, N (%) | 32 (54.2) | 8 (22.2) | 0.009 |
| COPD, N (%) | 19 (32.2) | 5 (13.9) | 0.046 |
| Obesity, N (%) | 19 (32.2) | 11 (30.6) | 0.87 |
| NYHA II, N (%) | 34 (57.6) | 21 (58.3) | 0.73 |
| NYHA III, N (%) | 24 (40.7) | 15 (41.7) |
BMI, body mass index; BSA, body surface area; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; ICD, implantable cardioverter defibrillator; CRT‐D, cardiac resynchronization therapy defibrillator; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association. We have reported in bold the statistically significant P‐value.